Načítá se...
The Value of EGFRvIII as the Target for Glioma Vaccines
Malignant brain tumors continue to be rapidly progressive and resistant to most treatments. Even with state-of-the-art standard of care (surgery, chemotherapy, and radiotherapy) long-term survival in the last 80 years improved from 6 to 15 months. Improved imaging has also likely contributed to prol...
Uloženo v:
| Vydáno v: | Am Soc Clin Oncol Educ Book |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4438702/ https://ncbi.nlm.nih.gov/pubmed/24857059 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14694/EdBook_AM.2014.34.42 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|